Arthneeti
Fundraise / allotmentNotable· Adverse for the businessFiled on BSE ·

Blue Jet Healthcare Limited announces Q1 FY2026-27 results and re-appointments

Blue Jet Healthcare · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read
₹293 CrFundraise / allotment

Key highlights

  • Reported Q1 FY2026-27 unaudited revenue from operations of ₹293.11 crore and net profit of ₹78.26 crore
  • Re-appointed Mr. Akshay Bansarilal Arora as Executive Chairman and Whole-Time Director for five years from April 13, 2027 to April 12, 2032, subject to shareholder approval
  • Re-appointed Mr. Shiven Akshay Arora as Managing Director for five years from April 13, 2027 to April 12, 2032, and re-appointed KKC & Associates LLP as Statutory Auditors for five years till FY2030-31, both subject to shareholder approval

Why it's rated notable: the year-on-year change is 14% (10% to 20% for adverse news)

Figures checked against the filing by a second AI read. About the business, not the share price.

Original filing

Board Meeting Outcome for Outcome Of Board Meeting Held On Monday, August 03, 2026

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Blue Jet Healthcare

Other fundraise / allotment filings this fortnight

All fundraise / allotment filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.